Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2020 - 2025)

Tarsus Pharmaceuticals has reported Cash & Equivalents over the past 6 years, most recently at $183.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $183.6 million for Q4 2025, up 93.68% from a year ago — trailing twelve months through Dec 2025 was $183.6 million (up 93.68% YoY), and the annual figure for FY2025 was $183.6 million, up 93.68%.
  • Cash & Equivalents for Q4 2025 was $183.6 million at Tarsus Pharmaceuticals, up from $112.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TARS hit a ceiling of $245.4 million in Q2 2022 and a floor of $66.0 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $175.4 million (2022), compared with a mean of $159.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 232.62% in 2021 and later plummeted 62.29% in 2023.
  • Tarsus Pharmaceuticals' Cash & Equivalents stood at $171.3 million in 2021, then tumbled by 58.17% to $71.7 million in 2022, then surged by 213.91% to $224.9 million in 2023, then tumbled by 57.85% to $94.8 million in 2024, then soared by 93.68% to $183.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $183.6 million (Q4 2025), $112.7 million (Q3 2025), and $96.6 million (Q2 2025) per Business Quant data.